Industry Research Reports

Home > Reports > Medical Care > Angiotensin II Receptor Blocker (ARBs) API - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Angiotensin II Receptor Blocker (ARBs) API - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030

Industry: Medical Care

Published: 2024-01-12

Pages: 109 Pages

Report ld: 2627250

Description
Table of Contents
Table of Figures
PDF Download

Description
Table of Contents
Table of Figures
PDF Download

Description

Valsartan, losartan, irbesartan and other “-sartan” drugs are a class of medicines known as angiotensin II receptor blocker (ARBs) used to treat high blood pressure and heart failure.

The global market for Angiotensin II Receptor Blocker (ARBs) API was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Angiotensin II Receptor Blocker (ARBs) API, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Angiotensin II Receptor Blocker (ARBs) API by region & country, by Type, and by Application.

The Angiotensin II Receptor Blocker (ARBs) API market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Angiotensin II Receptor Blocker (ARBs) API.

Market Segmentation

Report Metric
Details
Report Title
Angiotensin II Receptor Blocker (ARBs) API - Global Market Share and Ranking, Overall Sales and Demand Forecast 2024-2030
Global Angiotensin II Receptor Blocker (ARBs) API Companies Covered
Teva Pharmaceutical, Aurobindo Pharma, Viatris, Tianyu Pharma, Huahai Pharmaceutical, Menovo, Rundu Pharma, Kinglyuan Pharmaceutical, Second Pharma, Apeloa, Jiangxi Synergy Pharmaceutical
Global Angiotensin II Receptor Blocker (ARBs) API Market, by Region
North America (U.S., Canada, Mexico)

Europe (Germany, France, UK, Italy, etc.)

Asia Pacific (China, Japan, South Korea, Southeast Asia, India, etc.)

South America (Brazil, etc.)

Middle East and Africa (Turkey, GCC Countries, Africa, etc.)
Global Angiotensin II Receptor Blocker (ARBs) API Market, Segment by Type
Valsartan

Irbesartan

Telmisartan

Losartan

Candesartan

Olmesartan

Others
Global Angiotensin II Receptor Blocker (ARBs) API Market, Segment by Application
Essential Hypertension

Secondary Hypertension
Forecast Units
USD million in value
Report Coverage
Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Chapter Outline
Chapter 1: Introduces the report scope of the report, global total market size. This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 2: Detailed analysis of Angiotensin II Receptor Blocker (ARBs) API manufacturers competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Revenue of Angiotensin II Receptor Blocker (ARBs) API in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 6: Revenue of Angiotensin II Receptor Blocker (ARBs) API in country level. It provides sigmate data by Type, and by Application for each country/region.
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.

Table of Contents

 1 Market Overview
    1.1 Angiotensin II Receptor Blocker (ARBs) API Product Introduction
    1.2 Global Angiotensin II Receptor Blocker (ARBs) API Market Size Forecast
    1.3 Angiotensin II Receptor Blocker (ARBs) API Market Trends & Drivers
        1.3.1 Angiotensin II Receptor Blocker (ARBs) API Industry Trends
        1.3.2 Angiotensin II Receptor Blocker (ARBs) API Market Drivers & Opportunity
        1.3.3 Angiotensin II Receptor Blocker (ARBs) API Market Challenges
        1.3.4 Angiotensin II Receptor Blocker (ARBs) API Market Restraints
    1.4 Assumptions and Limitations
    1.5 Study Objectives
    1.6 Years Considered

 2 Competitive Analysis by Company
    2.1 Global Angiotensin II Receptor Blocker (ARBs) API Players Revenue Ranking (2023)
    2.2 Global Angiotensin II Receptor Blocker (ARBs) API Revenue by Company (2019-2024)
    2.3 Key Companies Angiotensin II Receptor Blocker (ARBs) API Manufacturing Base Distribution and Headquarters
    2.4 Key Companies Angiotensin II Receptor Blocker (ARBs) API Product Offered
    2.5 Key Companies Time to Begin Mass Production of Angiotensin II Receptor Blocker (ARBs) API
    2.6 Angiotensin II Receptor Blocker (ARBs) API Market Competitive Analysis
        2.6.1 Angiotensin II Receptor Blocker (ARBs) API Market Concentration Rate (2019-2024)
        2.6.2 Global 5 and 10 Largest Companies by Angiotensin II Receptor Blocker (ARBs) API Revenue in 2023
        2.6.3 Global Top Companies by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Angiotensin II Receptor Blocker (ARBs) API as of 2023)
    2.7 Mergers & Acquisitions, Expansion

 3 Segmentation by Type
    3.1 Introduction by Type
        3.1.1 Valsartan
        3.1.2 Irbesartan
        3.1.3 Telmisartan
        3.1.4 Losartan
        3.1.5 Candesartan
        3.1.6 Olmesartan
        3.1.7 Others
    3.2 Global Angiotensin II Receptor Blocker (ARBs) API Sales Value by Type
        3.2.1 Global Angiotensin II Receptor Blocker (ARBs) API Sales Value by Type (2019 VS 2023 VS 2030)
        3.2.2 Global Angiotensin II Receptor Blocker (ARBs) API Sales Value, by Type (2019-2030)
        3.2.3 Global Angiotensin II Receptor Blocker (ARBs) API Sales Value, by Type (%) (2019-2030)

 4 Segmentation by Application
    4.1 Introduction by Application
        4.1.1 Essential Hypertension
        4.1.2 Secondary Hypertension
    4.2 Global Angiotensin II Receptor Blocker (ARBs) API Sales Value by Application
        4.2.1 Global Angiotensin II Receptor Blocker (ARBs) API Sales Value by Application (2019 VS 2023 VS 2030)
        4.2.2 Global Angiotensin II Receptor Blocker (ARBs) API Sales Value, by Application (2019-2030)
        4.2.3 Global Angiotensin II Receptor Blocker (ARBs) API Sales Value, by Application (%) (2019-2030)

 5 Segmentation by Region
    5.1 Global Angiotensin II Receptor Blocker (ARBs) API Sales Value by Region
        5.1.1 Global Angiotensin II Receptor Blocker (ARBs) API Sales Value by Region: 2019 VS 2023 VS 2030
        5.1.2 Global Angiotensin II Receptor Blocker (ARBs) API Sales Value by Region (2019-2024)
        5.1.3 Global Angiotensin II Receptor Blocker (ARBs) API Sales Value by Region (2025-2030)
        5.1.4 Global Angiotensin II Receptor Blocker (ARBs) API Sales Value by Region (%), (2019-2030)
    5.2 North America
        5.2.1 North America Angiotensin II Receptor Blocker (ARBs) API Sales Value, 2019-2030
        5.2.2 North America Angiotensin II Receptor Blocker (ARBs) API Sales Value by Country (%), 2023 VS 2030
    5.3 Europe
        5.3.1 Europe Angiotensin II Receptor Blocker (ARBs) API Sales Value, 2019-2030
        5.3.2 Europe Angiotensin II Receptor Blocker (ARBs) API Sales Value by Country (%), 2023 VS 2030
    5.4 Asia Pacific
        5.4.1 Asia Pacific Angiotensin II Receptor Blocker (ARBs) API Sales Value, 2019-2030
        5.4.2 Asia Pacific Angiotensin II Receptor Blocker (ARBs) API Sales Value by Country (%), 2023 VS 2030
    5.5 South America
        5.5.1 South America Angiotensin II Receptor Blocker (ARBs) API Sales Value, 2019-2030
        5.5.2 South America Angiotensin II Receptor Blocker (ARBs) API Sales Value by Country (%), 2023 VS 2030
    5.6 Middle East & Africa
        5.6.1 Middle East & Africa Angiotensin II Receptor Blocker (ARBs) API Sales Value, 2019-2030
        5.6.2 Middle East & Africa Angiotensin II Receptor Blocker (ARBs) API Sales Value by Country (%), 2023 VS 2030

 6 Segmentation by Key Countries/Regions
    6.1 Key Countries/Regions Angiotensin II Receptor Blocker (ARBs) API Sales Value Growth Trends, 2019 VS 2023 VS 2030
    6.2 Key Countries/Regions Angiotensin II Receptor Blocker (ARBs) API Sales Value
    6.3 United States
        6.3.1 United States Angiotensin II Receptor Blocker (ARBs) API Sales Value, 2019-2030
        6.3.2 United States Angiotensin II Receptor Blocker (ARBs) API Sales Value by Type (%), 2023 VS 2030
        6.3.3 United States Angiotensin II Receptor Blocker (ARBs) API Sales Value by Application, 2023 VS 2030
    6.4 Europe
        6.4.1 Europe Angiotensin II Receptor Blocker (ARBs) API Sales Value, 2019-2030
        6.4.2 Europe Angiotensin II Receptor Blocker (ARBs) API Sales Value by Type (%), 2023 VS 2030
        6.4.3 Europe Angiotensin II Receptor Blocker (ARBs) API Sales Value by Application, 2023 VS 2030
    6.5 China
        6.5.1 China Angiotensin II Receptor Blocker (ARBs) API Sales Value, 2019-2030
        6.5.2 China Angiotensin II Receptor Blocker (ARBs) API Sales Value by Type (%), 2023 VS 2030
        6.5.3 China Angiotensin II Receptor Blocker (ARBs) API Sales Value by Application, 2023 VS 2030
    6.6 Japan
        6.6.1 Japan Angiotensin II Receptor Blocker (ARBs) API Sales Value, 2019-2030
        6.6.2 Japan Angiotensin II Receptor Blocker (ARBs) API Sales Value by Type (%), 2023 VS 2030
        6.6.3 Japan Angiotensin II Receptor Blocker (ARBs) API Sales Value by Application, 2023 VS 2030
    6.7 South Korea
        6.7.1 South Korea Angiotensin II Receptor Blocker (ARBs) API Sales Value, 2019-2030
        6.7.2 South Korea Angiotensin II Receptor Blocker (ARBs) API Sales Value by Type (%), 2023 VS 2030
        6.7.3 South Korea Angiotensin II Receptor Blocker (ARBs) API Sales Value by Application, 2023 VS 2030
    6.8 Southeast Asia
        6.8.1 Southeast Asia Angiotensin II Receptor Blocker (ARBs) API Sales Value, 2019-2030
        6.8.2 Southeast Asia Angiotensin II Receptor Blocker (ARBs) API Sales Value by Type (%), 2023 VS 2030
        6.8.3 Southeast Asia Angiotensin II Receptor Blocker (ARBs) API Sales Value by Application, 2023 VS 2030
    6.9 India
        6.9.1 India Angiotensin II Receptor Blocker (ARBs) API Sales Value, 2019-2030
        6.9.2 India Angiotensin II Receptor Blocker (ARBs) API Sales Value by Type (%), 2023 VS 2030
        6.9.3 India Angiotensin II Receptor Blocker (ARBs) API Sales Value by Application, 2023 VS 2030

 7 Company Profiles
    7.1 Teva Pharmaceutical
        7.1.1 Teva Pharmaceutical Profile
        7.1.2 Teva Pharmaceutical Main Business
        7.1.3 Teva Pharmaceutical Angiotensin II Receptor Blocker (ARBs) API Products, Services and Solutions
        7.1.4 Teva Pharmaceutical Angiotensin II Receptor Blocker (ARBs) API Revenue (US$ Million) & (2019-2024)
        7.1.5 Teva Pharmaceutical Recent Developments
    7.2 Aurobindo Pharma
        7.2.1 Aurobindo Pharma Profile
        7.2.2 Aurobindo Pharma Main Business
        7.2.3 Aurobindo Pharma Angiotensin II Receptor Blocker (ARBs) API Products, Services and Solutions
        7.2.4 Aurobindo Pharma Angiotensin II Receptor Blocker (ARBs) API Revenue (US$ Million) & (2019-2024)
        7.2.5 Aurobindo Pharma Recent Developments
    7.3 Viatris
        7.3.1 Viatris Profile
        7.3.2 Viatris Main Business
        7.3.3 Viatris Angiotensin II Receptor Blocker (ARBs) API Products, Services and Solutions
        7.3.4 Viatris Angiotensin II Receptor Blocker (ARBs) API Revenue (US$ Million) & (2019-2024)
        7.3.5 Tianyu Pharma Recent Developments
    7.4 Tianyu Pharma
        7.4.1 Tianyu Pharma Profile
        7.4.2 Tianyu Pharma Main Business
        7.4.3 Tianyu Pharma Angiotensin II Receptor Blocker (ARBs) API Products, Services and Solutions
        7.4.4 Tianyu Pharma Angiotensin II Receptor Blocker (ARBs) API Revenue (US$ Million) & (2019-2024)
        7.4.5 Tianyu Pharma Recent Developments
    7.5 Huahai Pharmaceutical
        7.5.1 Huahai Pharmaceutical Profile
        7.5.2 Huahai Pharmaceutical Main Business
        7.5.3 Huahai Pharmaceutical Angiotensin II Receptor Blocker (ARBs) API Products, Services and Solutions
        7.5.4 Huahai Pharmaceutical Angiotensin II Receptor Blocker (ARBs) API Revenue (US$ Million) & (2019-2024)
        7.5.5 Huahai Pharmaceutical Recent Developments
    7.6 Menovo
        7.6.1 Menovo Profile
        7.6.2 Menovo Main Business
        7.6.3 Menovo Angiotensin II Receptor Blocker (ARBs) API Products, Services and Solutions
        7.6.4 Menovo Angiotensin II Receptor Blocker (ARBs) API Revenue (US$ Million) & (2019-2024)
        7.6.5 Menovo Recent Developments
    7.7 Rundu Pharma
        7.7.1 Rundu Pharma Profile
        7.7.2 Rundu Pharma Main Business
        7.7.3 Rundu Pharma Angiotensin II Receptor Blocker (ARBs) API Products, Services and Solutions
        7.7.4 Rundu Pharma Angiotensin II Receptor Blocker (ARBs) API Revenue (US$ Million) & (2019-2024)
        7.7.5 Rundu Pharma Recent Developments
    7.8 Kinglyuan Pharmaceutical
        7.8.1 Kinglyuan Pharmaceutical Profile
        7.8.2 Kinglyuan Pharmaceutical Main Business
        7.8.3 Kinglyuan Pharmaceutical Angiotensin II Receptor Blocker (ARBs) API Products, Services and Solutions
        7.8.4 Kinglyuan Pharmaceutical Angiotensin II Receptor Blocker (ARBs) API Revenue (US$ Million) & (2019-2024)
        7.8.5 Kinglyuan Pharmaceutical Recent Developments
    7.9 Second Pharma
        7.9.1 Second Pharma Profile
        7.9.2 Second Pharma Main Business
        7.9.3 Second Pharma Angiotensin II Receptor Blocker (ARBs) API Products, Services and Solutions
        7.9.4 Second Pharma Angiotensin II Receptor Blocker (ARBs) API Revenue (US$ Million) & (2019-2024)
        7.9.5 Second Pharma Recent Developments
    7.10 Apeloa
        7.10.1 Apeloa Profile
        7.10.2 Apeloa Main Business
        7.10.3 Apeloa Angiotensin II Receptor Blocker (ARBs) API Products, Services and Solutions
        7.10.4 Apeloa Angiotensin II Receptor Blocker (ARBs) API Revenue (US$ Million) & (2019-2024)
        7.10.5 Apeloa Recent Developments
    7.11 Jiangxi Synergy Pharmaceutical
        7.11.1 Jiangxi Synergy Pharmaceutical Profile
        7.11.2 Jiangxi Synergy Pharmaceutical Main Business
        7.11.3 Jiangxi Synergy Pharmaceutical Angiotensin II Receptor Blocker (ARBs) API Products, Services and Solutions
        7.11.4 Jiangxi Synergy Pharmaceutical Angiotensin II Receptor Blocker (ARBs) API Revenue (US$ Million) & (2019-2024)
        7.11.5 Jiangxi Synergy Pharmaceutical Recent Developments

 8 Industry Chain Analysis
    8.1 Angiotensin II Receptor Blocker (ARBs) API Industrial Chain
    8.2 Angiotensin II Receptor Blocker (ARBs) API Upstream Analysis
        8.2.1 Key Raw Materials
        8.2.2 Raw Materials Key Suppliers
        8.2.3 Manufacturing Cost Structure
    8.3 Midstream Analysis
    8.4 Downstream Analysis (Customers Analysis)
    8.5 Sales Model and Sales Channels
        8.5.1 Angiotensin II Receptor Blocker (ARBs) API Sales Model
        8.5.2 Sales Channel
        8.5.3 Angiotensin II Receptor Blocker (ARBs) API Distributors

 9 Research Findings and Conclusion

 10 Appendix
    10.1 Research Methodology
        10.1.1 Methodology/Research Approach
        10.1.2 Data Source
    10.2 Author Details
    10.3 Disclaimer

Table of Figures

List of Tables
    Table 1. Angiotensin II Receptor Blocker (ARBs) API Market Trends
    Table 2. Angiotensin II Receptor Blocker (ARBs) API Market Drivers & Opportunity
    Table 3. Angiotensin II Receptor Blocker (ARBs) API Market Challenges
    Table 4. Angiotensin II Receptor Blocker (ARBs) API Market Restraints
    Table 5. Global Angiotensin II Receptor Blocker (ARBs) API Revenue by Company (2019-2024) & (US$ Million)
    Table 6. Global Angiotensin II Receptor Blocker (ARBs) API Revenue Market Share by Company (2019-2024)
    Table 7. Key Companies Angiotensin II Receptor Blocker (ARBs) API Manufacturing Base Distribution and Headquarters
    Table 8. Key Companies Angiotensin II Receptor Blocker (ARBs) API Product Type
    Table 9. Key Companies Time to Begin Mass Production of Angiotensin II Receptor Blocker (ARBs) API
    Table 10. Global Angiotensin II Receptor Blocker (ARBs) API Companies Market Concentration Ratio (CR5 and HHI)
    Table 11. Global Top Companies Market Share by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Angiotensin II Receptor Blocker (ARBs) API as of 2023)
    Table 12. Mergers & Acquisitions, Expansion Plans
    Table 13. Global Angiotensin II Receptor Blocker (ARBs) API Sales Value by Type: 2019 VS 2023 VS 2030 (US$ Million)
    Table 14. Global Angiotensin II Receptor Blocker (ARBs) API Sales Value by Type (2019-2024) & (US$ Million)
    Table 15. Global Angiotensin II Receptor Blocker (ARBs) API Sales Value by Type (2025-2030) & (US$ Million)
    Table 16. Global Angiotensin II Receptor Blocker (ARBs) API Sales Market Share in Value by Type (2019-2024) & (%)
    Table 17. Global Angiotensin II Receptor Blocker (ARBs) API Sales Market Share in Value by Type (2025-2030) & (%)
    Table 18. Global Angiotensin II Receptor Blocker (ARBs) API Sales Value by Application: 2019 VS 2023 VS 2030 (US$ Million)
    Table 19. Global Angiotensin II Receptor Blocker (ARBs) API Sales Value by Application (2019-2024) & (US$ Million)
    Table 20. Global Angiotensin II Receptor Blocker (ARBs) API Sales Value by Application (2025-2030) & (US$ Million)
    Table 21. Global Angiotensin II Receptor Blocker (ARBs) API Sales Market Share in Value by Application (2019-2024) & (%)
    Table 22. Global Angiotensin II Receptor Blocker (ARBs) API Sales Market Share in Value by Application (2025-2030) & (%)
    Table 23. Global Angiotensin II Receptor Blocker (ARBs) API Sales Value by Region: 2019 VS 2023 VS 2030 (US$ Million)
    Table 24. Global Angiotensin II Receptor Blocker (ARBs) API Sales Value by Region (2019-2024) & (US$ Million)
    Table 25. Global Angiotensin II Receptor Blocker (ARBs) API Sales Value by Region (2025-2030) & (US$ Million)
    Table 26. Global Angiotensin II Receptor Blocker (ARBs) API Sales Value by Region (2019-2024) & (%)
    Table 27. Global Angiotensin II Receptor Blocker (ARBs) API Sales Value by Region (2025-2030) & (%)
    Table 28. Key Countries/Regions Angiotensin II Receptor Blocker (ARBs) API Sales Value Growth Trends, (US$ Million): 2019 VS 2023 VS 2030
    Table 29. Key Countries/Regions Angiotensin II Receptor Blocker (ARBs) API Sales Value, (2019-2024) & (US$ Million)
    Table 30. Key Countries/Regions Angiotensin II Receptor Blocker (ARBs) API Sales Value, (2025-2030) & (US$ Million)
    Table 31. Teva Pharmaceutical Basic Information List
    Table 32. Teva Pharmaceutical Description and Business Overview
    Table 33. Teva Pharmaceutical Angiotensin II Receptor Blocker (ARBs) API Products, Services and Solutions
    Table 34. Revenue (US$ Million) in Angiotensin II Receptor Blocker (ARBs) API Business of Teva Pharmaceutical (2019-2024)
    Table 35. Teva Pharmaceutical Recent Developments
    Table 36. Aurobindo Pharma Basic Information List
    Table 37. Aurobindo Pharma Description and Business Overview
    Table 38. Aurobindo Pharma Angiotensin II Receptor Blocker (ARBs) API Products, Services and Solutions
    Table 39. Revenue (US$ Million) in Angiotensin II Receptor Blocker (ARBs) API Business of Aurobindo Pharma (2019-2024)
    Table 40. Aurobindo Pharma Recent Developments
    Table 41. Viatris Basic Information List
    Table 42. Viatris Description and Business Overview
    Table 43. Viatris Angiotensin II Receptor Blocker (ARBs) API Products, Services and Solutions
    Table 44. Revenue (US$ Million) in Angiotensin II Receptor Blocker (ARBs) API Business of Viatris (2019-2024)
    Table 45. Viatris Recent Developments
    Table 46. Tianyu Pharma Basic Information List
    Table 47. Tianyu Pharma Description and Business Overview
    Table 48. Tianyu Pharma Angiotensin II Receptor Blocker (ARBs) API Products, Services and Solutions
    Table 49. Revenue (US$ Million) in Angiotensin II Receptor Blocker (ARBs) API Business of Tianyu Pharma (2019-2024)
    Table 50. Tianyu Pharma Recent Developments
    Table 51. Huahai Pharmaceutical Basic Information List
    Table 52. Huahai Pharmaceutical Description and Business Overview
    Table 53. Huahai Pharmaceutical Angiotensin II Receptor Blocker (ARBs) API Products, Services and Solutions
    Table 54. Revenue (US$ Million) in Angiotensin II Receptor Blocker (ARBs) API Business of Huahai Pharmaceutical (2019-2024)
    Table 55. Huahai Pharmaceutical Recent Developments
    Table 56. Menovo Basic Information List
    Table 57. Menovo Description and Business Overview
    Table 58. Menovo Angiotensin II Receptor Blocker (ARBs) API Products, Services and Solutions
    Table 59. Revenue (US$ Million) in Angiotensin II Receptor Blocker (ARBs) API Business of Menovo (2019-2024)
    Table 60. Menovo Recent Developments
    Table 61. Rundu Pharma Basic Information List
    Table 62. Rundu Pharma Description and Business Overview
    Table 63. Rundu Pharma Angiotensin II Receptor Blocker (ARBs) API Products, Services and Solutions
    Table 64. Revenue (US$ Million) in Angiotensin II Receptor Blocker (ARBs) API Business of Rundu Pharma (2019-2024)
    Table 65. Rundu Pharma Recent Developments
    Table 66. Kinglyuan Pharmaceutical Basic Information List
    Table 67. Kinglyuan Pharmaceutical Description and Business Overview
    Table 68. Kinglyuan Pharmaceutical Angiotensin II Receptor Blocker (ARBs) API Products, Services and Solutions
    Table 69. Revenue (US$ Million) in Angiotensin II Receptor Blocker (ARBs) API Business of Kinglyuan Pharmaceutical (2019-2024)
    Table 70. Kinglyuan Pharmaceutical Recent Developments
    Table 71. Second Pharma Basic Information List
    Table 72. Second Pharma Description and Business Overview
    Table 73. Second Pharma Angiotensin II Receptor Blocker (ARBs) API Products, Services and Solutions
    Table 74. Revenue (US$ Million) in Angiotensin II Receptor Blocker (ARBs) API Business of Second Pharma (2019-2024)
    Table 75. Second Pharma Recent Developments
    Table 76. Apeloa Basic Information List
    Table 77. Apeloa Description and Business Overview
    Table 78. Apeloa Angiotensin II Receptor Blocker (ARBs) API Products, Services and Solutions
    Table 79. Revenue (US$ Million) in Angiotensin II Receptor Blocker (ARBs) API Business of Apeloa (2019-2024)
    Table 80. Apeloa Recent Developments
    Table 81. Jiangxi Synergy Pharmaceutical Basic Information List
    Table 82. Jiangxi Synergy Pharmaceutical Description and Business Overview
    Table 83. Jiangxi Synergy Pharmaceutical Angiotensin II Receptor Blocker (ARBs) API Products, Services and Solutions
    Table 84. Revenue (US$ Million) in Angiotensin II Receptor Blocker (ARBs) API Business of Jiangxi Synergy Pharmaceutical (2019-2024)
    Table 85. Jiangxi Synergy Pharmaceutical Recent Developments
    Table 86. Key Raw Materials Lists
    Table 87. Raw Materials Key Suppliers Lists
    Table 88. Angiotensin II Receptor Blocker (ARBs) API Downstream Customers
    Table 89. Angiotensin II Receptor Blocker (ARBs) API Distributors List
    Table 90. Research Programs/Design for This Report
    Table 91. Key Data Information from Secondary Sources
    Table 92. Key Data Information from Primary Sources
    Table 93. Business Unit and Senior & Team Lead Analysts
List of Figures
    Figure 1. Angiotensin II Receptor Blocker (ARBs) API Product Picture
    Figure 2. Global Angiotensin II Receptor Blocker (ARBs) API Sales Value, 2019 VS 2023 VS 2030 (US$ Million)
    Figure 3. Global Angiotensin II Receptor Blocker (ARBs) API Sales Value (2019-2030) & (US$ Million)
    Figure 4. Angiotensin II Receptor Blocker (ARBs) API Report Years Considered
    Figure 5. Global Angiotensin II Receptor Blocker (ARBs) API Players Revenue Ranking (2023) & (US$ Million)
    Figure 6. The 5 and 10 Largest Manufacturers in the World: Market Share by Angiotensin II Receptor Blocker (ARBs) API Revenue in 2023
    Figure 7. Angiotensin II Receptor Blocker (ARBs) API Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2019 VS 2023
    Figure 8. Valsartan Picture
    Figure 9. Irbesartan Picture
    Figure 10. Telmisartan Picture
    Figure 11. Losartan Picture
    Figure 12. Candesartan Picture
    Figure 13. Olmesartan Picture
    Figure 14. Others Picture
    Figure 15. Global Angiotensin II Receptor Blocker (ARBs) API Sales Value by Type (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 16. Global Angiotensin II Receptor Blocker (ARBs) API Sales Value Market Share by Type, 2023 & 2030
    Figure 17. Product Picture of Essential Hypertension
    Figure 18. Product Picture of Secondary Hypertension
    Figure 19. Global Angiotensin II Receptor Blocker (ARBs) API Sales Value by Application (2019 VS 2023 VS 2030) & (US$ Million)
    Figure 20. Global Angiotensin II Receptor Blocker (ARBs) API Sales Value Market Share by Application, 2023 & 2030
    Figure 21. North America Angiotensin II Receptor Blocker (ARBs) API Sales Value (2019-2030) & (US$ Million)
    Figure 22. North America Angiotensin II Receptor Blocker (ARBs) API Sales Value by Country (%), 2023 VS 2030
    Figure 23. Europe Angiotensin II Receptor Blocker (ARBs) API Sales Value (2019-2030) & (US$ Million)
    Figure 24. Europe Angiotensin II Receptor Blocker (ARBs) API Sales Value by Country (%), 2023 VS 2030
    Figure 25. Asia Pacific Angiotensin II Receptor Blocker (ARBs) API Sales Value (2019-2030) & (US$ Million)
    Figure 26. Asia Pacific Angiotensin II Receptor Blocker (ARBs) API Sales Value by Country (%), 2023 VS 2030
    Figure 27. South America Angiotensin II Receptor Blocker (ARBs) API Sales Value (2019-2030) & (US$ Million)
    Figure 28. South America Angiotensin II Receptor Blocker (ARBs) API Sales Value by Country (%), 2023 VS 2030
    Figure 29. Middle East & Africa Angiotensin II Receptor Blocker (ARBs) API Sales Value (2019-2030) & (US$ Million)
    Figure 30. Middle East & Africa Angiotensin II Receptor Blocker (ARBs) API Sales Value by Country (%), 2023 VS 2030
    Figure 31. Key Countries/Regions Angiotensin II Receptor Blocker (ARBs) API Sales Value (%), (2019-2030)
    Figure 32. United States Angiotensin II Receptor Blocker (ARBs) API Sales Value, (2019-2030) & (US$ Million)
    Figure 33. United States Angiotensin II Receptor Blocker (ARBs) API Sales Value by Type (%), 2023 VS 2030
    Figure 34. United States Angiotensin II Receptor Blocker (ARBs) API Sales Value by Application (%), 2023 VS 2030
    Figure 35. Europe Angiotensin II Receptor Blocker (ARBs) API Sales Value, (2019-2030) & (US$ Million)
    Figure 36. Europe Angiotensin II Receptor Blocker (ARBs) API Sales Value by Type (%), 2023 VS 2030
    Figure 37. Europe Angiotensin II Receptor Blocker (ARBs) API Sales Value by Application (%), 2023 VS 2030
    Figure 38. China Angiotensin II Receptor Blocker (ARBs) API Sales Value, (2019-2030) & (US$ Million)
    Figure 39. China Angiotensin II Receptor Blocker (ARBs) API Sales Value by Type (%), 2023 VS 2030
    Figure 40. China Angiotensin II Receptor Blocker (ARBs) API Sales Value by Application (%), 2023 VS 2030
    Figure 41. Japan Angiotensin II Receptor Blocker (ARBs) API Sales Value, (2019-2030) & (US$ Million)
    Figure 42. Japan Angiotensin II Receptor Blocker (ARBs) API Sales Value by Type (%), 2023 VS 2030
    Figure 43. Japan Angiotensin II Receptor Blocker (ARBs) API Sales Value by Application (%), 2023 VS 2030
    Figure 44. South Korea Angiotensin II Receptor Blocker (ARBs) API Sales Value, (2019-2030) & (US$ Million)
    Figure 45. South Korea Angiotensin II Receptor Blocker (ARBs) API Sales Value by Type (%), 2023 VS 2030
    Figure 46. South Korea Angiotensin II Receptor Blocker (ARBs) API Sales Value by Application (%), 2023 VS 2030
    Figure 47. Southeast Asia Angiotensin II Receptor Blocker (ARBs) API Sales Value, (2019-2030) & (US$ Million)
    Figure 48. Southeast Asia Angiotensin II Receptor Blocker (ARBs) API Sales Value by Type (%), 2023 VS 2030
    Figure 49. Southeast Asia Angiotensin II Receptor Blocker (ARBs) API Sales Value by Application (%), 2023 VS 2030
    Figure 50. India Angiotensin II Receptor Blocker (ARBs) API Sales Value, (2019-2030) & (US$ Million)
    Figure 51. India Angiotensin II Receptor Blocker (ARBs) API Sales Value by Type (%), 2023 VS 2030
    Figure 52. India Angiotensin II Receptor Blocker (ARBs) API Sales Value by Application (%), 2023 VS 2030
    Figure 53. Angiotensin II Receptor Blocker (ARBs) API Industrial Chain
    Figure 54. Angiotensin II Receptor Blocker (ARBs) API Manufacturing Cost Structure
    Figure 55. Channels of Distribution (Direct Sales, and Distribution)
    Figure 56. Bottom-up and Top-down Approaches for This Report
    Figure 57. Data Triangulation

Description

Valsartan, losartan, irbesartan and other “-sartan” drugs are a class of medicines known as angiotensin II receptor blocker (ARBs) used to treat high blood pressure and heart failure.

The global market for Angiotensin II Receptor Blocker (ARBs) API was estimated to be worth US$ million in 2023 and is forecast to a readjusted size of US$ million by 2030 with a CAGR of % during the forecast period 2024-2030.

According to our research, the global market for medical devices is estimated at US$ 603 billion in the year 2023, and will be growing at a CAGR of 5% during next six years. The global healthcare spending contributes to occupy 10% of the global GDP and is continuously rising in recent years due to the increasing health needs of the aging population, the growing prevalence of chronic and infectious diseases and the expansion of emerging markets. The medical devices market plays a significant role in the healthcare industry. The market is driven by several factors, including the increasing demand for advanced healthcare services globally, advancements in medical technology, growing geriatric population, rising healthcare expenditure, and increasing awareness about early disease diagnosis and treatment.

Report Scope
This report aims to provide a comprehensive presentation of the global market for Angiotensin II Receptor Blocker (ARBs) API, focusing on the total sales revenue, key companies market share and ranking, together with an analysis of Angiotensin II Receptor Blocker (ARBs) API by region & country, by Type, and by Application.

The Angiotensin II Receptor Blocker (ARBs) API market size, estimations, and forecasts are provided in terms of sales revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. With both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Angiotensin II Receptor Blocker (ARBs) API.

Market Segmentation